People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CytomX Therapeutics, Inc. | — | Biotechnology | Series C | $143.0M | $392.9M | 2012 |
Charles W. Homcy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles W. Homcy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Matthew Young | 1 | 7 |
| Michael E. Pfau | 1 | 6 |
| Elaine Jones | 1 | 6 |
| Nancy Stagliano | 1 | 5 |
| Alan Heeger | 1 | 5 |
| Gary Wilcox | 1 | 4 |
| Sean McCarthy | 1 | 3 |
| Frederick W Gluck | 1 | 3 |
| Elaine V. Jones | 1 | 3 |
| Tim W. Shannon | 1 | 2 |
| Frederick Gluck | 1 | 2 |
| Chris Ogden | 1 | 2 |
| Halley Gilbert | 1 | 2 |
| Mani Mohindru | 1 | 2 |
| James Meyers | 1 | 2 |
| Alan Ashworth | 1 | 2 |
| Wayne Chu | 1 | 1 |
| Lloyd Rowland | 1 | 1 |
| Alan W. Heeger | 1 | 1 |
| Jeff Landau | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.